PTC Therapeutics (PTCT) Receives Daily Media Impact Rating of 0.20
Press coverage about PTC Therapeutics (NASDAQ:PTCT) has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PTC Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.5674749448152 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of PTCT opened at $46.55 on Friday. PTC Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $52.95. The firm has a market capitalization of $2.34 billion, a P/E ratio of -23.04 and a beta of 1.95. The company has a current ratio of 4.34, a quick ratio of 4.18 and a debt-to-equity ratio of 0.55.
PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.15. PTC Therapeutics had a negative net margin of 25.03% and a negative return on equity of 27.41%. The company had revenue of $68.74 million for the quarter, compared to analysts’ expectations of $69.83 million. analysts anticipate that PTC Therapeutics will post -1.48 EPS for the current year.
In related news, EVP Neil Gregory Almstead sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $48.31, for a total value of $966,200.00. Following the sale, the executive vice president now owns 37,154 shares in the company, valued at $1,794,909.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.50% of the company’s stock.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.